Dabrafenib might also be used for objectives not provided in this medicine guide. Using dabrafenib with trametinib may increase your risk of developing a particular type of skin cancer. Inform your doctor if you see any new skin symptoms. Making use of dabrafenib with trametinib may increase your risk of developing a particular type of skin cancer. Tell your physician if you observe any new skin symptoms such as redness, excrescences, sores that will not heal, or a mole that has altered in dimension or color. Both males and females making use of dabrafenib should use efficient contraception to stop pregnancy. Dabrafenib can cause or hurt an expected child birth flaws if the mother or dad is using this medication. Keep utilizing birth control for at least 2 weeks after your last dose. If a maternity happens while either the papa or the mom is utilizing dabrafenib, inform your doctor right away. If you use dabrafenib and trametinib together: Keep using birth control for at least 4 months after your last dosage of these two medications. Dabrafenib can make hormonal birth control less effective, consisting of contraceptive pill, injections, implants, skin patches, and genital rings. Your doctor will perform blood tests to make certain you have the appropriate tumor type to be treated with dabrafenib. Your physician will require to examine your skin every 2 months while you are making use of dabrafenib, and for approximately 6 months after your treatment finishes. Take the medicine as quickly as you can, yet avoid the missed out on dosage if your next dose schedules in less than 6 hrs.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions
** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.
CID | MolecularFormula | MolecularWeight | CanonicalSMILES | IsomericSMILES | InChI | InChIKey | IUPACName | XLogP | ExactMass | MonoisotopicMass | TPSA | Complexity | Charge | HBondDonorCount | HBondAcceptorCount | RotatableBondCount | HeavyAtomCount | IsotopeAtomCount | AtomStereoCount | DefinedAtomStereoCount | UndefinedAtomStereoCount | BondStereoCount | DefinedBondStereoCount | UndefinedBondStereoCount | CovalentUnitCount |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
44462760 | C23H20F3N5O2S2 | 519.6 | CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F | CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F | InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29) | BFSMGDJOXZAERB-UHFFFAOYSA-N | N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide | 4.8 | 519.10105173 | 519.10105173 | 148 | 817 | 0 | 2 | 11 | 6 | 35 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Plex Page is a Biology & Health Sciences "Online Knowledge Base," where a machine summarizes all the summaries.
Contact
General contact: [email protected]